Erratum: Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

被引：0

作者：

I Breitkreutz

M S Raab

S Vallet

T Hideshima

N Raje

C Mitsiades

D Chauhan

Y Okawa

N C Munshi

P G Richardson

K C Anderson

机构：

来源：

Leukemia | 2008年 / 22卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Correction to: Leukemia (2008) 22, 1925–1932; doi:10.1038/leu.2008.174; published online 3 July 2008 Owing to a typesetting error, Figure 2b of the above article was published incorrectly. The correct figure is reproduced here. The publisher apologizes for this error and any inconvenience it may have caused.

引用

页码：1973 / 1973

共 50 条

[41] Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone
San-Miguel, Jesus F.
Dimopoulos, Meletios A.
Stadtmauer, Edward A.
Rajkumar, S. Vincent
Siegel, David
Bravo, Marie-Laure
Olesnyckyj, Marta
Knight, Robert D.
Zeldis, Jerome B.
Harousseau, Jean-Luc
Weber, Donna M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (01): : 38 - 43
[42] Halofuginone Inhibits Osteoclastogenesis and Enhances Osteoblastogenesis by Regulating Th17/Treg Cell Balance in Multiple Myeloma Mice with Bone Lesions
Wu, Xiaofei
Sun, Qiong
Li, Xiang
Jiang, Lin
Chen, Li
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2024, 40 (03) : 407 - 414
[43] p38MAPK inhibitor LSN2322600 modulates the bone marrow microenvironment and inhibits osteoclastogenesis in multiple myeloma.
Ishitsuka, Kenji
Hideshima, Teru
Neri, Paola
Vallet, Sonia
Shiraishi, Norihiko
Raje, Noopur
Shen, Zhenxin
Kiziltepe, Tanyel
Ocio, Enrique M.
Podar, Klaus
Chauhan, Dharminder
Munshi, Nikhil
Campbell, Robert M.
De Dios, Alfonso
Shih, Chuan
Starling, James J.
Tamura, Kazuo
Anderson, Kenneth C.
BLOOD, 2006, 108 (11) : 350B - 350B
[44] Factors associated with non-adherence to lenalidomide in patients with multiple myeloma.
Leng, Siyang
Lentzsch, Suzanne
Chen, Yizhen
Accordino, Melissa Kate
Wright, Jason Dennis
Neugut, Alfred I.
Hershman, Dawn L.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[45] Factors Associated with Dose Modification of Lenalidomide Plus Dexamethasone Therapy in Multiple Myeloma
Kado, Yoko
Tsujimoto, Masayuki
Fuchida, Shin-ichi
Okano, Akira
Hatsuse, Mayumi
Murakami, Satoshi
Sugii, Hikofumi
Ueda, Kumi
Toda, Yuki
Minegaki, Tctsuya
Nishiguchi, Kohshi
Muraki, Yuichi
Shimazaki, Chihiro
Ashihara, Eishi
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2020, 43 (08) : 1253 - 1258
[46] Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
Croucher, PI
Shipman, CM
Perry, M
Lippitt, J
Asosingh, K
van Beek, EJR
Van Camp, B
Russell, RGG
Dunstan, C
Vanderkerken, K
BONE, 2001, 28 (05) : S81 - S81
[47] Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
Croucher, PI
Shipman, CM
Lippitt, J
Perry, M
Asosingh, K
Hijzen, A
Brabbs, AC
van Beek, EJR
Holen, I
Skerry, TM
Dunstan, CR
Russell, GR
Van Camp, B
Vanderkerken, K
BLOOD, 2001, 98 (13) : 3534 - 3540
[48] Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Siegel, David S.
Dimopoulos, Meletios A.
Ludwig, Heinz
Facon, Thierry
Goldschmidt, Hartmut
Jakubowiak, Andrzej
San-Miguel, Jesus
Obreja, Mihaela
Blaedel, Julie
Stewart, A. Keith
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) : 728 - +
[49] Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma
Amsler, Isabel G.
Jeker, Barbara
Taleghani, Behrouz Mansouri
Bacher, Ulrike
Betticher, Daniel
Egger, Thomas
Zander, Thilo
Luethi, Jean-Marc
Novak, Urban
Pabst, Thomas
LEUKEMIA & LYMPHOMA, 2019, 60 (02) : 511 - 514
[50] Bone disease in multiple myeloma: new markers, new treatments
Joshua, D
INTERNAL MEDICINE JOURNAL, 2001, 31 (05) : 261 - 263

← 1 2 3 4 5 →